EICHORPublic-registry site landscape for NCT07750665, “FXS6837 for the Treatment for IgAN Patients（Longterm Study）”, a Primary IgAN study sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07750665 (registry record) |
| Study title | FXS6837 for the Treatment for IgAN Patients（Longterm Study） |
| Official title | A Study to Evaluate the Long-term Efficacy and Safety of FXS6837 in IgAN Patients |
| Sponsor | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
| Condition(s) | Primary IgAN |
| Phase | PHASE2 |
| Listed sites | 1 |
| Intervention(s) | FXS6837 Capsule |
| Site countries | China |
At Peking University First Hospital — one of the facilities listed on this trial — 6 other studies are actively recruiting Primary IgAN patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07750665.
Eichor generates a preliminary site-risk snapshot for NCT07750665 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
